NEW YORK (GenomeWeb News) – Hepregen and The Hamner Institutes for Health Sciences today announced a deal aimed at research to be conducted by the two partners.

Under the terms of the agreement, the two entities will carry out R&D work directed at defining the basic concepts "regarding the potential for new microliver products," and new applications and assay methods for Hepregen's existing microliver products.

The research will be led by Edward LeCluyse, associate investigator at Hamner, and Jack McGeehan, Hepregen's VP of Operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.